INIT: Pudafensine targets major unmet needs in ED and vulvodynia, with pivotal data expected by 2026

About this update from Initiator Pharma A/s

Pudafensine, a novel monoamine modulator, is advancing in clinical trials for ED and vulvodynia, targeting large unmet needs with strong safety and efficacy data. The company is well-funded through 2027, focusing on partnerships and expects key clinical and business milestones within the next 12-14 months.Based on This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Initiator Pharma A/s